Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.
The intensive intervention was four hours a day, five days a week, for a total of 200 hours of face-to-face instruction, and neuroimaging revealed brain connectivity changes. 
Macrophage cells require agility to scavenge and digest dead cells and prevent an immune response to self. In lupus, the macrophages lose that agility.
This improvement in cognition persists despite a high-glycemic-index diet, a possible risk factor for Alzheimer’s.
Neuron-derived microRNAs obtained from blood samples may correlate with treatment response and could aid the search for new therapeutics.
UAB pathologist also leads a trainee in producing software to improve the quality and efficiency of perinatal autopsies.
Increased risk of major adverse cardiac events after the later surgery persists for one year.
Between-hospital variations in active treatment explain much of the difference seen in infants born at 22 to 24 weeks of gestation.
The protective effect is achieved by reducing acute inflammation in the spleen and the left ventricle of the heart.
UAB discovery gives better understanding of and potential therapies for septic shock and reperfusion injuries.